Depo-Provera Lawsuit: The Settlement, Its Deadline and the Court's Orders in MDL No. 3140

What the Depo-Provera lawsuit claims

The Judicial Panel on Multidistrict Litigation centralized the cases of, in the words the court quotes, “plaintiffs who allege they suffered intracranial meningiomas caused by use of Depo-Provera or a generic version thereof.” (Case Management Order No. 14, In re Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, MDL No. 3140, No. 3:25-md-3140-MCR-HTC, ECF No. 738, at 2 (N.D. Fla. Aug. 10, 2026) (quoting the Panel's Transfer Order))

The court describes the claims as “personal injury claims related to depot medroxyprogesterone acetate products manufactured by Defendants, including Depo-Provera, Depo-SubQ Provera 104, and any authorized generic versions of such products” (Case Management Order No. 14, In re Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, MDL No. 3140, No. 3:25-md-3140-MCR-HTC, ECF No. 738, at 2 (N.D. Fla. Aug. 10, 2026)). Its orders call each of those products an MPA Product.

The label has changed during the case. The court notes that “on December 12, 2025, the FDA approved Pfizer’s request to add a warning regarding meningioma to the US label for Depo-Provera.” (Pretrial Order No. 30, In re Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, MDL No. 3140, No. 3:25-md-3140-MCR-HTC, ECF No. 534, at 3 (N.D. Fla. Jan. 27, 2026))

These are claims and allegations. No document read for this page decides whether the drug is the cause of any meningioma, and the court records that the settlement admits nothing: “There is no admission of fault or liability by Defendants in connection with the settlement.” (Case Management Order No. 14, In re Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, MDL No. 3140, No. 3:25-md-3140-MCR-HTC, ECF No. 738, at 1 (N.D. Fla. Aug. 10, 2026) n.1)

The Depo-Provera lawsuit settlement

The court first recorded it on June 15, 2026: “on June 15, 2026, Leadership Counsel announced a Settlement of a majority of the claims in the MDL and New York state court.” (Case Management Order No. 12, In re Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, MDL No. 3140, No. 3:25-md-3140-MCR-HTC, ECF No. 701, at 2 (N.D. Fla. July 27, 2026)) Its later order describes it: “which the Court understands is memorialized in an agreement dated July 22, 2026, that will offer a substantial percentage of Plaintiffs with cases pending in this MDL the opportunity to resolve their claims.” (Case Management Order No. 14, In re Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, MDL No. 3140, No. 3:25-md-3140-MCR-HTC, ECF No. 738, at 1 (N.D. Fla. Aug. 10, 2026))

The court has not approved its terms, and says why: “The Settlement is not subject to a fairness determination by the Court because this MDL is not a class action.” (Case Management Order No. 12, In re Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, MDL No. 3140, No. 3:25-md-3140-MCR-HTC, ECF No. 701, at 3 (N.D. Fla. July 27, 2026) n.4) It adds: “Importantly, this is a private agreement governed by a confidentiality agreement.” (Case Management Order No. 12, In re Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, MDL No. 3140, No. 3:25-md-3140-MCR-HTC, ECF No. 701, at 3 (N.D. Fla. July 27, 2026))

Who is eligible is defined by the agreement. As the court records counsel's explanation: “They explained that eligibility for participation is defined within the MSA and will not be impacted by any future Court ruling on the legal issues that remain outstanding in the MDL.” (Case Management Order No. 12, In re Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, MDL No. 3140, No. 3:25-md-3140-MCR-HTC, ECF No. 701, at 3 (N.D. Fla. July 27, 2026))

The court appointed an administrator: “BrownGreer PLC is appointed as the Settlement Administrator.” (Case Management Order No. 13, In re Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, MDL No. 3140, No. 3:25-md-3140-MCR-HTC, ECF No. 711, at 1 (N.D. Fla. Aug. 5, 2026)) And: “BrownGreer will use the information collected from individuals and their counsel to perform eligibility determinations for participation in the settlement program.” (Case Management Order No. 13, In re Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, MDL No. 3140, No. 3:25-md-3140-MCR-HTC, ECF No. 711, at 2 (N.D. Fla. Aug. 5, 2026))

On timing, the court records what the parties told it: “The Parties represent that Settlement registration should be completed in November 2026, with the claims process beginning to be completed and payments beginning to roll out by the first quarter of 2027.” (Case Management Order No. 12, In re Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, MDL No. 3140, No. 3:25-md-3140-MCR-HTC, ECF No. 701, at 3 (N.D. Fla. July 27, 2026)) That is the parties' representation, not a date the court set.

The deadline to register

The court records the deadline: “The Court understands that the deadline for claimants to register to participate in the Settlement Program is November 30, 2026, and that, thereafter, any potential claimants identified to and/or finally determined by the Settlement Administrator to be ineligible for the Settlement Program will be identified to the Court.” (Case Management Order No. 14, In re Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, MDL No. 3140, No. 3:25-md-3140-MCR-HTC, ECF No. 738, at 1 (N.D. Fla. Aug. 10, 2026))

For someone with no case on file, the court opened a separate docket and limited who may use it: “The only Plaintiffs permitted to file complaints on the administrative docket are those who (a) signed engagement letters with counsel to pursue their MPA Product claim on or before June 11, 2026, and (b) are eligible to participate in the Settlement Program.” (Case Management Order No. 14, In re Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, MDL No. 3140, No. 3:25-md-3140-MCR-HTC, ECF No. 738, at 12 (N.D. Fla. Aug. 10, 2026)) “The Court will enforce the Parties’ confidentiality agreement and establish a no-fee administrative docket, as requested.” (Case Management Order No. 12, In re Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, MDL No. 3140, No. 3:25-md-3140-MCR-HTC, ECF No. 701, at 4 (N.D. Fla. July 27, 2026))

So two dates in the court's words matter to a person who has not filed: June 11, 2026, for signing with a lawyer, and November 30, 2026, for registering. If you signed with a lawyer, ask whether a complaint was filed for you and whether your claim is registered.

If a case does not settle

The court will still decide the open legal questions for those cases: “The Court will rule on these issues for purposes of cases that are ineligible for the Settlement or individuals who opt out.” (Case Management Order No. 12, In re Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, MDL No. 3140, No. 3:25-md-3140-MCR-HTC, ECF No. 701, at 3 (N.D. Fla. July 27, 2026) n.5)

It names two kinds of plaintiff who are not eligible: those “not eligible to participate in the Settlement Program because of the date on which they commenced their action against Defendants.” (Case Management Order No. 14, In re Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, MDL No. 3140, No. 3:25-md-3140-MCR-HTC, ECF No. 738, at 12 (N.D. Fla. Aug. 10, 2026)), and those “not eligible to participate in the Settlement Program because of the timing of the individual’s meningioma diagnosis relative to their last use of an MPA Product.” (Case Management Order No. 14, In re Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, MDL No. 3140, No. 3:25-md-3140-MCR-HTC, ECF No. 738, at 12 (N.D. Fla. Aug. 10, 2026))

Its order for continuing cases requires proof of use: “(1) All available documentation establishing that the Litigating Plaintiff used an MPA Product; and (2) a declaration setting forth the first date when the Litigating Plaintiff used an MPA Product, the last date when the Litigating Plaintiff used an MPA Product, and the intervening date ranges when the Litigating Plaintiff used an MPA Product.” (Case Management Order No. 14, In re Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, MDL No. 3140, No. 3:25-md-3140-MCR-HTC, ECF No. 738, at 18 (N.D. Fla. Aug. 10, 2026)) And proof of injury: “All available documentation concerning the Litigating Plaintiff’s meningioma diagnosis, Litigating Plaintiffs’ course of treatment for meningioma (including any radiation or surgery), and any ongoing or permanent injuries alleged by Litigating Plaintiffs to be related to MPA Product use.” (Case Management Order No. 14, In re Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, MDL No. 3140, No. 3:25-md-3140-MCR-HTC, ECF No. 738, at 18 (N.D. Fla. Aug. 10, 2026))

Then mediation: “All Litigating Plaintiffs who have fulfilled the requirements set forth in this Order must participate in mediation before Magistrate Judge Hope Cannon.” (Case Management Order No. 14, In re Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, MDL No. 3140, No. 3:25-md-3140-MCR-HTC, ECF No. 738, at 24 (N.D. Fla. Aug. 10, 2026)) And a conference in person: “A Plaintiff’s unexcused failure to appear at a scheduled Status Conference will result in Plaintiff’s case being dismissed with prejudice.” (Case Management Order No. 14, In re Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, MDL No. 3140, No. 3:25-md-3140-MCR-HTC, ECF No. 738, at 25 (N.D. Fla. Aug. 10, 2026))

Filing a new Depo-Provera lawsuit

A case filed after that order is a future filed case, and the order sets its first steps. Notices to preserve records are due “Within 60 days after the date a Future Filed Plaintiff files her case in the MDL or her case is transferred to this Court by the JPML.” (Case Management Order No. 14, In re Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, MDL No. 3140, No. 3:25-md-3140-MCR-HTC, ECF No. 738, at 14 (N.D. Fla. Aug. 10, 2026))

And for an earlier diagnosis: “Counsel for each Future Filed Plaintiff and each pro se Future Filed Plaintiff who alleges they developed a meningioma from an MPA Product prior to March 27, 2024, must, within 30 days after filing in or transfer to” (Case Management Order No. 14, In re Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, MDL No. 3140, No. 3:25-md-3140-MCR-HTC, ECF No. 738, at 25 (N.D. Fla. Aug. 10, 2026)) this MDL, serve and file “a Certification that provides the basis for the Future Filed Plaintiff’s assertions that her claims are not barred by the applicable statute of limitations.” (Case Management Order No. 14, In re Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, MDL No. 3140, No. 3:25-md-3140-MCR-HTC, ECF No. 738, at 26 (N.D. Fla. Aug. 10, 2026)) So for a meningioma that developed before March 27, 2024, the order asks at once why the claim is not too late.

No document read for this page says which state's filing period applies to a Depo-Provera claim or when its clock starts, so this page counts no deadline. The product liability calculator on this site quotes each state's period for a product claim from its code, and a lawyer can say which applies to you.

The records the court asks for

Proof has been required from the beginning: the parties “agree that all Plaintiffs with filed cases must provide (a) initial documentary proof of use for each named Defendant’s product, and (b) initial documentary proof of their alleged meningioma injury.” (Pretrial Order No. 17, In re Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, MDL No. 3140, No. 3:25-md-3140-MCR-HTC, ECF No. 178, at 1 (N.D. Fla. Mar. 14, 2025))

In practice that means pharmacy and prescription records or clinic records that show the injections and their dates, the imaging and pathology reports for the diagnosis, the records of any surgery or radiation, and the bills. Keep them together, with the dates.

The label warning the court describes came on December 12, 2025, so the dates of your injections and of your diagnosis are the facts a lawyer will ask for first.

Where the federal cases are

The MDL is No. 3140, before Judge M. Casey Rodgers, master docket 3:25-md-3140. The Panel's report lists the date transferred as February 7, 2025.

The Panel's report of October 1, 2026 lists 6,412 actions now pending in it, and 6,524 in total since it began. The figures are the report's, as of its date, and this page prints them with that date.

The court set a hearing on the general causation motions: “The hearing on those motions is scheduled for September 18, 2026, following the next CMC.” (Case Management Order No. 12, In re Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, MDL No. 3140, No. 3:25-md-3140-MCR-HTC, ECF No. 701, at 2 (N.D. Fla. July 27, 2026)) The latest entry on the court's list of its orders, read for this page, is dated September 4, 2026: “September 04, 2026 Case Management Order 17 Appointment of lien resolution master” (U.S. District Court for the Northern District of Florida, MDL No. 3140 website, Orders By Date (read Oct. 6, 2026)) This page read no ruling on those motions.

What this page does not say about money

No document read for this page states what the settlement pays, how it divides the money, or a verdict or trial figure, so this page states none and does not estimate one.

What the checker above does is add up the costs you can document, so you have one figure to bring to a lawyer. It is the sum of what you enter and nothing else.

Talking to a lawyer about a Depo-Provera lawsuit

This site is not a law firm, does not refer anyone to a lawyer, and cannot say what the settlement or a lawyer would recover. The questions that decide a claim are ones the settlement's terms and a lawyer answer: whether you can take part, whether your claim is registered in time, and what continuing a case would require.

Bring the injection records with their dates, the diagnosis and treatment records, your record of costs, and the orders this page quotes.